The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared with placebo atop standard care (annualized rate 1.11 vs 1.31, P =0.049), ...

Although cigarette smoking remains the single largest risk factor, there is proof that shows many women, over the age of 40, are developing COPD even in those who are non-smokers ...